Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Kaposi Sarcoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
4 drugs · 3 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pomalidomide | Approved | Phase 2 | 3 | 1 | 0 | 5 | 1 | US | Feb 8, 2013 | Jan 10, 2012 |
| Doxorubicin | Approved | Phase 3 | 0 | 0 | 6 | 11 | 1 | US | Nov 17, 1995 | 1999-03 |
| Alitretinoin | Approved | Phase 2 | 0 | 0 | 0 | 2 | 2 | EU, US | Feb 2, 1999 | — |
| Vinblastine | Approved | — | 0 | 0 | 0 | 0 | 1 | US | Apr 29, 1987 | — |
| Paclitaxel | Phase 3 | Phase 3 | 1 | 0 | 2 | 3 | 0 | — | — | 1999-03 |
| Bleomycin | Phase 3 | Phase 3 | 0 | 0 | 3 | 7 | 0 | — | — | — |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 3 | 7 | 0 | — | — | — |
| Etoposide | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | Nov 18, 2011 |
| Daunorubicin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | — |
| Nivolumab | Phase 2 | Phase 2 | 4 | 2 | 0 | 7 | 0 | — | — | Oct 21, 2015 |
| Pembrolizumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Apr 4, 2016 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 29, 2021 |
| Ixazomib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 7, 2023 |
| Nirogacestat | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 17, 2026 |
| Bevacizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Feb 26, 2003 |
| Interferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | — |
| Ipilimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 21, 2015 |
| Bexarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Daromun | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 9, 2023 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-06 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 27, 2010 |
| Mitoxantrone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Selumetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 15, 2012 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-01 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2021 |
| Vismodegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-06 |
| Cabozantinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 22, 2021 |
| Bortezomib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 22, 2010 |
| Interferon Beta-1b | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Sorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 2, 2006 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.